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Background. 2-microglobulin (2-m) is considered a major
pathogenic factor in dialysis-related amyloidosis (DRA), often
seen in long-term dialysis patients. No effective therapy for this
severely debilitating disease is currently available. Lixelle, an
adsorption column, has been developed for the elimination of
2-m; the efficacy of this column has been evaluated in this study.
Methods. Seventeen hemodialysis patients with DRA were
first treated with high-flux dialysis for a minimum of 1 year.
This was followed by 1-year treatment with Lixelle column
connected in series to the high-flux dialyzer. Treatments were
used three times a week for both phases of this study. During
the study period, 2-m, pinch strength, motor terminal latency,
and activities of daily living were evaluated.
Results. After 1-year treatment with high-flux dialysis the
2-m level remained unchanged; however, after 1-year treat-
ment with the addition of the Lixelle column, 2-m level
decreased significantly from 34.5  8.4 mg/L to 28.8  7.3
mg/L (P  0.05). After 1 year of Lixelle column use, the
pinch strength increased from 6.8  4.7 pounds to 9.1  5.5
pounds (P  0.01), and the median motor terminal latency
was significantly reduced from 5.1  1.0 mseconds to 4.5 
1.1 mseconds. A significant improvement was also observed in
the activities of daily living score of the upper extremities.
Conclusion. These results suggest that the addition of Lix-
elle to the high-flux dialyzer is associated with a significant
clinical improvement in DRA patients.
Dialysis-related amyloidosis (DRA) is one of the ma-
jor complications seen in long-term hemodialysis patients
[1]. It is associated with excruciating and debilitating
pain and deterioration in quality of life and activities of
daily living of dialysis patients. The major pathogenesis
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of DRA is reported to be the accumulation of 2-micro-
globulin (2-m) [2] and the modification of 2-m by ad-
vanced glycation end products [3]. Bone cysts around
the joints and carpal tunnel syndrome are the early symp-
toms of DRA.
It has been reported that the accumulation of about
400 to 600 g of 2-m is associated with the onset of DRA
[4] and that plasma concentration of 2-m well reflects
the captation pool of 2-m [5]. Reduction in 2-m concen-
tration and maintenance of a low serum level along with
the prevention of 2-m accumulation are, therefore, es-
sential to treat and prevent DRA.
An adsorbent column (Lixelle; Kaneka Co., Osaka,
Japan) for direct hemoperfusion has been commercially
available since 1996 in Japan [6] and can efficiently re-
move 2-m [7]. Most of the published reports about the
use of Lixelle described only the subjective evaluations
of patients [8–10].
This study reports the effects of Lixelle on 2-m
levels and on DRA as assessed by objective measure-
ment of pinch strength and motor terminal latency in
addition to the subjective evaluations by a visual analog
scale (VAS) (0 to 10 cm) for joint pain and a question-
naire based on the modified Stanford Health Assessment
Questionnaire (m-HAQ) for activities of daily living.
METHODS
This study was started in January 1999 at the Center
of Blood Purification Therapy in Wakayama Medical
University and proceeded with collaboration of 13 re-
lated facilities listed in the Acknowledgments section.
The dialysis circumstances were similar in all the facilities
with quite homogeneous patient population. Further-
more, the physicians and staff in charge of the facilities
were either part of the study or were very familiar with
the study. Additionally, the research staff visited these
facilities frequently before the study to ensure uniformity
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Table 1. Patient profiles
Characteristic Number
Gender
Men:women 6:11
Underlying renal disease
Chronic glomerulonephritis 12
Diabetic nephropathy 2
Systemic lupus erythematosus 1
Nephrosclerosis 1
Unknown 1
Age years 57.17.5 (4369)
Time on hemodialysis years 20.24.5 (1329)
of treatment and during the study to closely monitor
that treatments were not modified.
Twenty-two hemodialysis patients, who met all of the
following inclusion criteria and provided written in-
formed consent, were enrolled. The inclusion criteria
were (1) the presence of tissue deposition of amyloid
with 2-m confirmed by surgery or biopsy; (2) had been
treated by dialysis for at least 10 years; (3) had under-
gone carpal tunnel surgery; and (4) bone cysts were
detected by x-ray imaging.
First, the patients were dialyzed by high-flux dialyzer
for at least 1 year before the start of this study. Hemodial-
ysis conditions were kept constant from 12 months before
the start of the Lixelle hemoperfusion study until the
end of the study (June 2000). All of the patients had
suffered from several symptoms of DRA and these
symptoms did not improve by the use of high-flux dia-
lyzer alone. New medications, such as steroids, that may
have influenced DRA symptoms were not permitted.
The demographic data of the patients are shown in
Table 1.
Five patients out of 22 dropped out of this study. Four
patients voluntarily withdrew from the study and one
patient transferred to another hospital for surgery. The
remaining 17 patients with 34 hands finished the study
and participated in the questionnaire survey. Pinch
strength was measured in 34 hands; however, the data
from one hand of a patient who underwent carpal tunnel
surgery during the 1-year period of Lixelle therapy
were excluded. Thus, the pinch strength data from 33
hands have been analyzed. Three patients refused the
motor nerve study because of pain and the motor termi-
nal latency of the ulnar nerve was measured in the 27
hands (excluding the one operated hand and six hands in
three patients who refused the test). The motor terminal
latency of the median nerve was measured in the 26
hands, excluding the above seven hands and another
hand with missing baseline measurement.
Fig. 1. Schema of extracorporeal circulation during the treatment.
Adsorbent column for 2-m
The Lixelle column contains 350 mL of porous cellu-
lose adsorbent beads with a diameter of about 460 m,
in which a hexadecyl group with high hydrophobicity is
used as ligand. It incorporates peptides and proteins with
a molecular weight of 4000 to 20,000 by the molecule
sieving effect of the surface pores of the beads. It adsorbs
only hydrophobic proteins, such as 2-m, by binding with
the hydrophobic hexadecyl hydrocarbonate group
[6, 10]. The beads in the Lixelle column have the capac-
ity to adsorb 2-m at 1 mg or more per 1 mL of the beads
[11]. The Lixelle column containing 350 mL beads is
clinically used and can remove 200 to 300 mg of 2-m in
one regular hemodialysis therapy [12].
Extracorporeal circulation
The treatment was performed by connecting the col-
umn to the hemodialysis circuit before the dialyzer, in
series at the usual maintenance hemodialysis without
using any other specific equipment (Fig. 1). The column
was added before the dialyzer for several reasons. First,
the primary objective of the study was to assess the
efficacy of the column in removing the 2-m. Thus, it
was better to let the patient’s undialyzed blood go
through the column first to assess its efficacy in undis-
turbed condition. Second, as reported by Nakazawa [13],
there are no differences in 2-m clearance whether the
column was connected before (89.4  9.2 mL/min) or
after (88.7  9.8 mL/min) a dialyzer. Third, the column
was placed before the dialyzer to prevent the potential
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contamination of the column from any chemicals coming
out of the dialyzer if the dialyzer was not cleaned properly.
Although the Lixelle column is highly effective, ad-
verse events, such as the aggravation of dialysis-related
hypotension and worsening of anemia, have been pre-
viously reported [6, 14]. In order to avoid these complica-
tions, two steps were taken: (1) the use of recombinant
human erythropoietin in those study patients was initi-
ated earlier than is usually used in Japan; and (2) to
prevent hypotension, 100 to 200 mL saline was used to
prime the system, thus reducing the large extracorporeal
blood volume and preventing hypotension.
During the year prior to the 1-year hemoperfusion
study, patients were treated for 4 hours three times a
week by high-flux dialysis and, during the 12 months
of hemoperfusion, dialysis schedule and dialyzer type
remained unchanged. During both these periods, the
endotoxins concentration was kept below 50 EU/L. The
dialyzer membranes were polysulfone, cellulose triace-
tate, modified regenerated cellulose, and polyarylether-
sulfon. All dialyzes were used only once and were not
reused.
Strength test with pinch test
In all patients, tip pinch strength was measured by a
Pinch Gauge (B&L Engineering Co., Los Angeles, CA,
USA) with the same limb positioned so that measure-
ment errors due to variation in position could be elimi-
nated [15]. The subjects were seated with their shoulder
adducted and neutrally rotated, elbow flexed at 90, fore-
arm in neutral position, and wrist between 0 and 30
dorsiflexion and between 0 and 15 ulnar deviation.
They placed the tip of their thumb on the side of the
Pinch Gauge, the tip of their index finger on the other
side of the Pinch Gauge as if to make an “O,” and their
other fingers was curled into their palm. After the subject
was positioned appropriately, he or she was asked to
pinch the gauge maximally and the strength was mea-
sured in pounds. This measurement was repeated three
times in each hand and the mean value was calculated.
Motor terminal latency
Median motor terminal latency [16] was measured
with a Nervepace Electroneurometer (Neurotron Medi-
cal, Lawrenceville, NJ, USA) by placing the stimulating
probe over the median nerve and positioning electrodes
at the base of first phalanx of the thumb on the thenar
eminence. The motor terminal latency was measured
five times and the mean value was calculated. The dis-
tance from the electrode on the thenar eminence to the
stimulating probe was set at 7 cm. Ulnar motor terminal
latency was measured by placing the stimulating probe
over the ulnar nerve and electrodes were positioned at
the base of the lateral aspect of fifth metacarpopha-
langeal joint on the hypothenar eminence. The motor
terminal latency was measured five times and the mean
value was obtained. Once again, the distance from the
electrode on the hypothenar eminence to the stimulating
probe was set at 7 cm. Normal range of the motor termi-
nal latency for median nerve is between 3.80 mseconds
and 4.34 mseconds and from 3.12 mseconds to 3.52 msec-
onds for ulnar nerve according to clinical studies con-
ducted by Rossier and Blair [17] using Nervepace Elec-
troneurometer.
In order to exclude the heterogeneity, all measure-
ments of tip pinch strength and motor terminal latency
were conducted by the same designated observers, vis-
iting all facilities participating in the study and using the
same Pinch Gauge and Nervepace Neurometer.
Questionnaire survey
The subjective symptoms, including the frequency of
nocturnal awakening by pain and the severity index of
upper and lower limb joint pain, was evaluated by a
questionnaire. Activities of daily living were evaluated
by using m-HAQ questionnaire [18]. The questionnaire
of m-HAQ included eight categories: (1) dressing and
grooming, (2) arising, (3) eating, (4) walking, (5) main-
taining hygiene, (6) reaching, (7) gripping, and (8) other
activities. Scores for the degree of difficulty were defined
as follows: 0, without any difficulty; 1, with some diffi-
culty; 2, with much difficulty; 3, unable to do, for indepen-
dent daily living activities such as dressing and grooming,
eating, hygiene, reaching, and gripping for the upper
extremities, and arising, walking, and other activities for
the lower extremities.
The subjective symptoms, including the frequency of
nocturnal awakening by pain, were evaluated by a ques-
tionnaire using VAS (0 to 10 cm) for joint pain in upper
(shoulder, elbow, wrist, and finger) and lower (coxa, knee,
and foot) extremities.
Statistical analysis
The statistical significance was analyzed by the paired
Student t test and the Wilcoxon signed-rank test.
RESULTS
At the start of high-flux dialysis the2-m level was 34.6
9.3 mg/L and remained unchanged after a minimum of
1 year of three times a week high-flux dialysis. Thus, at
the start of 1 year of Lixelle therapy the 2-m level
was 34.5  8.4 mg/L, after 1 year of adding the Lixelle,
the 2-m level decreased significantly to 28.8  7.3 mg/L
(P  0.05) (Fig. 2).
The average change in 2-m concentration by one reg-
ular hemodialysis session (predialysis to postdialysis) us-
ing Lixelle (in combination with high-flux dialyzer) was
22 mg/L (from 29.9  7.7 mg/L to 7.9  1.7 mg/L, P 
0.0001), a 74%  6% reduction.
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Fig. 2. Change in 2-microglobulin (2-m) levels. All patients were
dialyzed by high-flux dialyzer for at least 1 year before the start of this
study, and hemodialysis conditions were kept constant from 12 months
before the start of the hemoperfusion study until the end of the study.
During the 1 year of high-flux dialysis alone, the 2-m level remained
unchanged (34.6  9.3 mg/L and 34.5  8.4 mg/L at 1 year before the
start of this study and at the start of this study). In contrast, 1 year of
Lixelle column addition was associated with a significant decline in
2-m level, from 34.5  8.4 mg/L to 28.8  7.3 mg/L.
Fig. 3. Change in pinch strength. Pinch strength was significantly in-
creased with 1 year of Lixelle therapy from 6.8  4.7 pounds to 9.1 
5.5 pounds (P  0.001).
Pinch strength was significantly increased after 1 year
of Lixelle therapy from 6.8  4.7 pounds to 9.1  5.5
pounds (P  0.001) (Fig. 3). After Lixelle treatment,
the median motor terminal latency was significantly re-
duced from 5.1  1.0 mseconds to 4.5  1.1 mseconds
(P  0.05) (Fig. 4). However, the ulnar motor terminal
latency was not changed during the column use, 3.4 
0.6 mseconds and 3.5  0.3 mseconds before and after
the therapy, respectively.
Fig. 4. Change in motor terminal latency. (A ) After 1 year of Lixelle
therapy, the median motor terminal latency was significantly reduced
from 5.1  1.0 mseconds to 4.5  1.1 mseconds (P  0.05). (B ) The
ulnar motor terminal latency was not changed, 3.4  0.6 mseconds and
3.5  0.3 mseconds before and after the therapy, respectively.
There were significant improvements in VAS evalua-
tions for the joint pain (P  0.05) (Fig. 5). Moreover,
the frequency of nocturnal awakening was reduced from
2.6  2.5 times/day to 0.5  0.8 times/day (P  0.01)
(Fig. 6).
Total activities of daily living scores for upper extremi-
ties was significantly reduced from 49 to 29 (P  0.005)
during the study; however, the score for lower extremi-
ties was not changed from 45 to 42 (Fig. 6).
The improvement in the median motor terminal la-
tency was observed only in those who had abnormal
baseline value. The abnormal value was defined as 4.5
mseconds, and in this group treatment with Lixellewas
associated with significant improvement from 5.5  0.8
mseconds to 4.7  1.1 mseconds (P  0.005) (Fig. 7).
However, if the baseline value was 4.5 mseconds, the
use of Lixelle was not associated with any improve-
ment. Significant negative correlation was observed be-
tween the change in pinch strength and change in median
motor terminal latency (r  0.412, P  0.0367) (Fig. 8).
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Fig. 5. Change in Visual Analogue Scale (VAS) evaluations for joint
pain. VAS score was significantly reduced from 5.7  2.1 points to 4.1 
2.4 points before and after the therapy.
DISCUSSION
The study patients had demonstrable clinical involve-
ment with DRA and, as expected, high levels of 2-m.
These patients showed no improvement in their clinical
severity of DRA after being on high-flux dialysis for a
minimum of 1 year. Further, there was no significant
reduction in their 2-m levels after the use of high-flux
dialysis. However, after 1 year of using the Lixelle
column, significant reduction in 2-m levels and clinical
symptoms were documented. This strongly suggested
that the reduction in 2-m with the use of the column
was responsible for these improvements.
Previous studies on the clinical efficacy of the Lixelle
column have been case reports and have mainly de-
scribed improvements in subjective symptoms [9], reduc-
tion of amyloid deposits around the retinal vessels [19],
decrease in bone cyst area [20], or improvement in nerve
conduction time [21]. However, these case reports in-
volved a small number of patients. The present study is
the first to evaluate the effect of the combination of high-
flux dialyzer and Lixelle on DRA and 2-m levels in
a relatively large group of patients. The study also com-
pared the effects of the column with high-flux dialyzer
with those of high-flux dialyzer alone. In addition to using
a subjective questionnaire, objective measurements of
pinch strength and motor terminal latency were also
evaluated.
DRA has been thought to be related to the accumula-
tion of 2-m [2] and the modification of 2-m by advanced
glycation end products [3]. A three-pool model, intravas-
cular, rapid-turnover, and slow-turnover extravascular
pool, has been proposed to simulate the kinetics of 2-m
in dialysis patients [22]. With conventional hemodialysis
alone, it is difficult to remove 2-m from the slow-turn-
Fig. 6. Change in subjective evaluations. (A ) Change in frequency
of nocturnal awakening. The frequency of nocturnal awakening was
reduced from 2.6  2.5 times/day to 0.5  0.8 times/day (P  0.01).
(B ) Change in activities of daily living (ADL) score [modified Stanford
Health Assessment Questionnaire (m-HAQ)]. Activities of daily liv-
ing score was calculated by using the m-HAQ. The questionnaire of
m-HAQ included eight categories, which were dressing and grooming,
arising, eating, walking, maintaining hygiene, reaching, gripping, and
other activities. Activities for daily living for upper extremities were
evaluated using dressing and grooming, eating, maintaining hygiene,
reaching, and gripping. Activities for daily living for lower extremities
were evaluated using arising, walking, and other activities. Total scores
for upper extremities were improved from 49 to 29 (P 0.005) but those
for lower extremities were not improved from 45 to 42 (not significant).
over extravascular pool, even with the use of a high-flux
dialyzer, since very little 2-m is mobilized from this pool
during the hemodialysis session. Compared to high-flux
dialyzer, the Lixelle column can remove a great quan-
tity of 2-m and at a faster rate. About 30 minutes after
starting the treatment, 2-m concentration at the column
inlet was reported to be about half of the initial concen-
tration, and this very low plasma concentration was
maintained throughout the 4 hours of treatment [8, 19].
We speculate that the greater efficacy of Lixelle ther-
apy leading to a very low plasma concentration of 2-m
in the intravascular pool permits a rapid and large flux
from the extravascular pool allowing a larger net removal
during each treatment. This larger concentration gradi-
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Fig. 7. Comparison of changes in median motor terminal latency be-
tween the basal 4.5 mseconds group and the basal 4.5 mseconds
group. Comparison of the abnormal group with a median motor terminal
latency 4.5 mseconds (19 hands) and the normal group with a motor
terminal latency4.5 mseconds (7 hands) showed marked improvement
in the abnormal group (P  0.005).
ent from the start of therapy between slow and rapid-
turnover pools permits more efficient removal of the
total body 2-m and improvement in the clinical picture
of DRA. In our study, the data for the removal of 2-m
by the high-flux dialyzer alone was not collected. Re-
moval by the Lixelle column is so pronounced, how-
ever, that the blood entering the dialyzer has very low
2-m levels, making it difficult to assess the high-flux
dialyzer’s contribution. Furthermore, previous reports
[12, 19] have described that the 2-m reduction by Lix-
elle was greater than by dialysis alone.
Moreover, the Lixelle column has been reported
to remove other biologically active substances, such as
cytokines, interleukin-1 (IL-1), IL-6, and tumor necrosis
factor-	 (TNF-	), endotoxins, and peptidoglycans [23, 24].
Thus, the removal of these inflammatory mediators may
also modify 2-m generation. Future studies should try
to focus on these possibilities.
Although our study suffers from the lack of a simulta-
neous control group, the 22 patients were on high-flux
dialysis for a minimum of 1 year prior to starting on
Lixelle treatment and the historical control data show
that high-flux dialysis was not very effective. During the
1 year of high-flux dialysis, the 2-m level remained es-
sentially unchanged (34.6  9.3 mg/L and 34.5  8.4
mg/L at the beginning and end of high-flux dialysis).
In contrast, 1 year of using the Lixelle column was
associated with a significant decline in 2-m level. It is
interesting that all study patients suffered from severe
symptoms of DRA and, even after 1 year of high-flux
dialysis, the symptoms did not improve, but with Lix-
Fig. 8. Correlation between the improvement of pinch strength and
median motor terminal latency. There was a significant correlation
between the improvement of pinch strength and median motor terminal
latency (r  0.412, P  0.0367).
elle therapy, associated with a drop in 2-m level, there
was a marked improvement in DRA symptoms.
The improvement of activities of daily living score
occurred only for the upper extremity and not for the
lower extremity. The frequency of nocturnal awakening
was significantly reduced during the hemoperfusion
study. It is unclear why the activities of daily living im-
provement was not significant for the lower extremity.
We can speculate that the weight-bearing lower extrem-
ity takes longer to show any improvement. Moreover,
the reduction in the frequency of nocturnal awakening
was ascribed to the improvement in joint pain. The exact
reason for the improvement is speculative but may be
related to the removal by the column of biologically
active substances causing pain.
During the Lixelle column use, there was an im-
provement in motor terminal latency but only for the
median and not for the ulnar nerve (Fig. 4). Since the
median nerve, unlike the ulnar nerve, passes through a
tight tunnel, compression of the nerve due to the accumu-
lation of 2-m and inflammatory edema produced by
cellular infiltration causes carpal tunnel. The Lixelle
column may have removed sufficient 2-m and reduced
inflammatory edema from the carpal tunnel, thus causing
an improvement in median motor terminal latency. We
speculate that the reduction of inflammatory edema at
the carpal tunnel caused the improvement of pinch
strength and the improvement of both the joint pain
and the inflammatory edema were responsible for the
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improvement of the activities of daily living of the upper
extremity.
Comparison of the group with a basal median motor
terminal latency 4.5 mseconds (abnormal, 19 hands)
and the group with a basal motor terminal latency 4.5
mseconds (normal, 7 hands) showed a marked improve-
ment in the group with abnormal value (Fig. 7), sug-
gesting that severe carpal tunnel syndrome may be an
indication for the use of the Lixelle column. Interest-
ingly, there was a significant correlation between the
improvement of pinch strength and motor terminal la-
tency of median nerve (r  0.412, P  0.0367) (Fig. 8).
Improvement of pinch strength was more marked in
patients showing greater improvement of the motor ter-
minal latency.
Previous studies have reported [6, 14] adverse events
associated with Lixelle. These included the aggravation
of dialysis-related hypotension and worsening of anemia.
However, we did not encounter these problems, perhaps
due to the early initiation of recombinant human eryth-
ropoietin and the use of extra saline. Plasma levels of
myeloperoxidase and polymorphonuclear leukocyte
elastase as an index of bioincompatibillity have been
reported to be markedly elevated in patients receiving
hemodialysis with the Lixelle column [14]. In the fu-
ture, this problem should be further studied.
CONCLUSION
One year of using the Lixelle column improved 2-m
levels, the pinch strength, the median motor terminal
latency, and the questionnaire results for activities of
daily living in DRA patients. These results suggest that
signs and symptoms of DRA are subjectively and objec-
tively improved by Lixelle. One-year follow-up was
not considered to be long enough to improve lytic lesions,
thus this was not studied. Further studies with longer
follow-up are needed to clarify the efficacy of Lixelle
treatment for the change in bone cysts or the improve-
ment in the range of motion restricted by joint pain.
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